Open access
Open access
Powered by Google Translator Translator

TB/Non-TB Mycobacterial Infections

M-A | Assessing the diagnostic performance of new commercial IGRAs for Mycobacterium tuberculosis infection

24 Jan, 2023 | 14:25h | UTC

Assessing the diagnostic performance of new commercial IGRAs for Mycobacterium tuberculosis infection: a systematic review and meta-analysis – Clinical Infectious Diseases

 

Commentary on Twitter

 


Brief review and algorithm | Management of latent tuberculosis infection

23 Jan, 2023 | 13:35h | UTC

Management of Latent Tuberculosis Infection – JAMA (free for a limited period)

 


Consensus statement | Use of a 4-month treatment regimen for drug susceptible TB in children with uncomplicated disease

18 Jan, 2023 | 14:25h | UTC

Consensus statement on the use of a four-month treatment regimen for drug susceptible tuberculosis in children (< 10 years of age) with uncomplicated disease – Australian Government Department of Health and Aged Care

 


WHO consolidated guidelines on tuberculosis | Drug-resistant tuberculosis treatment, 2022 update

12 Jan, 2023 | 13:30h | UTC

WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update – World Health Organization

See also:

WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment

WHO consolidated guidelines on tuberculosis: module 2: screening: systematic screening for tuberculosis disease

WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection, 2021 update

WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents

 


RCT | A 24-week, all-oral regimen for rifampin-resistant tuberculosis

12 Jan, 2023 | 13:27h | UTC

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis – New England Journal of Medicine

Commentary: Trial results show superiority of shorter, all-oral treatment for drug-resistant TB – CIDRAP

 


Collection of Cochrane evidence on diagnosing tuberculosis.

1 Dec, 2022 | 13:56h | UTC

Collection of Cochrane evidence on diagnosing tuberculosis – Cochrane Library

 


WHO Global tuberculosis report 2022.

29 Nov, 2022 | 14:25h | UTC

Global tuberculosis report 2022 – World Health Organization

News Release: Tuberculosis deaths and disease increase during the COVID-19 pandemic – World Health Organization

Video Summary: WHO Global Tuberculosis Report 2022: Key findings and messages – World Health Organization

 

Commentary on Twitter (thread – click for more)

 


RCT | Evaluation of two short, standardized regimens for the treatment of rifampicin-resistant tuberculosis.

15 Nov, 2022 | 12:57h | UTC

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial – The Lancet

Commentary: 

Shorter treatment effective for drug-resistant tuberculosis – University College London

Shorter Treatment Regimen for Drug-Resistant TB is More Effective – Health Policy Watch

 


RCT | Efficacy of 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide for treatment of fluoroquinolone-sensitive MDR-TB.

9 Nov, 2022 | 12:11h | UTC

9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea – The Lancet (link to abstract – $ for full-text)

 


RCT | A digital medication event reminder may improve quality of life and reduce costs in patients with tuberculosis.

1 Nov, 2022 | 11:48h | UTC

Effect of Digital Medication Event Reminder and Monitor-Observed Therapy vs Standard Directly Observed Therapy on Health-Related Quality of Life and Catastrophic Costs in Patients With Tuberculosis: A Secondary Analysis of a Randomized Clinical Trial – JAMA Network Open

Commentaries:

Digital Medication Device Improves Quality of Life, Reduces Costs for TB Patients – HCP Live

Digital Medication Monitor Linked to Better HRQOL, Lower Costs for Tuberculosis – AJMC

 

Commentary on Twitter

https://twitter.com/JAMANetworkOpen/status/1570442333686042628

 


Systematic Review | Global frequency and clinical features of stroke in patients with tuberculous meningitis.

6 Sep, 2022 | 14:19h | UTC

Global Frequency and Clinical Features of Stroke in Patients With Tuberculous Meningitis: A Systematic Review – JAMA Network Open

 


RCT | Bedaquiline–Pretomanid–Linezolid regimens for drug-resistant tuberculosis.

2 Sep, 2022 | 13:16h | UTC

Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Three drug regimen with Linezolid 600 mg tied to better outcomes in drug-resistant TB – Medical Dialogues

 


Perspective | Ending tuberculosis in a post-COVID-19 world: a person-centered, equity-oriented approach.

19 Aug, 2022 | 16:02h | UTC

Ending tuberculosis in a post-COVID-19 world: a person-centred, equity-oriented approach – The Lancet Infectious Diseases

 

Commentary on Twitter

 


Perspective | Epidemiological approach to ending tuberculosis in high-burden countries.

19 Aug, 2022 | 15:59h | UTC

Epidemiological approach to ending tuberculosis in high-burden countries – The Lancet

 

Commentary on Twitter

 


M-A | Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course.

15 Aug, 2022 | 12:21h | UTC

Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis – The Lancet Global Health

Invited Commentary: Infant BCG vaccination is beneficial, but not sufficient – The Lancet Global Health

News Release: BCG vaccine prevents tuberculosis in young children, but not adults – Boston University School of Public Health

 

Commentary from the author on Twitter (thread – click for more)

 


M-A | Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006–2021.

3 Aug, 2022 | 14:04h | UTC

Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006–2021: a systematic review and meta-analysis – BMJ Open

 


M-A | Lung cancer occurrence after an episode of tuberculosis.

29 Jul, 2022 | 12:28h | UTC

Lung cancer occurrence after an episode of tuberculosis: a systematic review and meta-analysis – European Respiratory Review

 


Review | Tuberculosis in cirrhosis – A diagnostic and management conundrum.

7 Jul, 2022 | 12:18h | UTC

Tuberculosis in Cirrhosis – A Diagnostic and Management Conundrum – Journal of Clinical and Experimental Hepatology

 


M-A: Treatment outcomes among pregnant patients with multidrug-resistant tuberculosis.

15 Jun, 2022 | 10:47h | UTC

Treatment Outcomes Among Pregnant Patients With Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis – JAMA Network Open

 

Commentary on Twitter

 


Systematic Review: Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.

25 May, 2022 | 10:46h | UTC

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin – Cochrane Library

Summary: Xpert MTB/XDR, a rapid test for resistance to tuberculosis drugs – Cochrane Library

 


Modeling Study: 20% of multi-drug resistant tuberculosis cases in children could be averted by household testing and treatment.

25 May, 2022 | 10:44h | UTC

News Release: 20% of multi-drug resistant tuberculosis cases in children could be averted by household testing and treatment – London School of Hygiene & Tropical Medicine

Original Study: The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study – The Lancet Global Health

Invited Commentary: Investing in drug-resistant tuberculosis household contact management and preventive treatment – The Lancet Global Health

 


WHO calls for shorter drug course for resistant TB.

4 May, 2022 | 11:08h | UTC

WHO calls for shorter drug course for resistant TB – CIDRAP

Rapid communication: Key changes to the treatment of drug-resistant tuberculosis – World Health Organization

 


Review: Anti-tuberculosis treatment strategies and drug development: challenges and priorities.

1 May, 2022 | 23:23h | UTC

Anti-tuberculosis treatment strategies and drug development: challenges and priorities – Nature Reviews Microbiology (if the link is paywalled, try this one)

News Release: A major update on global tuberculosis fight – Hackensack Meridian Health

 

Commentary on Twitter

 


Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.

27 Apr, 2022 | 07:52h | UTC

Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views – Cochrane Library

Summary: Rapid molecular tests for tuberculosis and tuberculosis drug resistance: the views and experiences of people who are tested and healthcare providers – Cochrane Library

Commentary: Molecular tests for TB: Global rollout of rapid molecular tests for tuberculosis over the last 12 years – Liverpool School of Tropical Medicine

 


Drug resistant TB – latest developments in epidemiology, diagnostics and management.

13 Apr, 2022 | 10:09h | UTC

Drug resistant TB – latest developments in epidemiology, diagnostics and management – International Journal of Infectious Diseases

Related:

Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.

WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment

Randomized Trial: 9-month Treatment for Multi-drug Resistant TB is as Effective as 24-month Treatment

Canadian Tuberculosis Standards – 8th Edition.

Guideline: Treatment of Drug-Resistant Tuberculosis

NICE Guideline: Tuberculosis

The Lancet Commission: Management of Multidrug-resistant and Incurable Tuberculosis

Regimens to Treat Multidrug-resistant Tuberculosis: Past, Present and Future Perspectives

 


Stay Updated in Your Specialty

No spam, just news.